

MAURA T. HEALEY Governor KIMBERLEY DRISCOLL Lieutenant Governor The Commonwealth of Massachusetts Executive Office of Health and Human Services Department of Public Health

Bureau of Health Professions Licensure 250 Washington Street, Boston, MA 02108-4619

> KATHLEEN E. WALSH Secretary ROBERT GOLDSTEIN, MD, PhD Commissioner

> > Tel: 617-624-6000 www.mass.gov/dph

Board of Registration in Pharmacy Drug Control Program

Policy 2023-06: Schedules II and III Quantity Limits

<u>M.G.L. 94C § 23(d)</u> restricts the prescribing and dispensing quantities of Schedules II and III controlled substances to a 30-day supply at a time. However, this statute also allows certain medications for the treatment of "minimal brain dysfunction" and narcolepsy to be prescribed and dispensed for up to a 60-day supply.

For the purposes of this policy, "minimal brain dysfunction" shall include Attention Deficit Disorder ("ADD") and / Attention Deficit/Hyperactivity Disorder ("ADHD") or other accepted term for an inattention or impulsivity-hyperactivity disorder.

Medications eligible to be provided in a 60-day supply for minimal brain dysfunction and narcolepsy include dextroamphetamine sulfate, methylphenidate hydrochloride, and any other mixed amphetamine salts or derivatives that are Food and Drug Administration ("FDA") approved for the treatment of these conditions.

Although there is no requirement for the diagnosis to be indicated on the prescription, the diagnosis must be verified and documented either on the prescription or in the pharmacy computer system prior to dispensing.

Please direct any questions to: Pharmacy.Admin@mass.gov